Related Experiment Video

Updated: Aug 5, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

Pharmacotherapeutic strategy in heart failure

P Dominiak1

  • 1Institute for Experimental and Clinical Pharmacology and Toxicology, University Clinic Lübeck, Germany. dominiak@medinf.mu-luebeck.de

Clinical Nephrology
|September 14, 2002
PubMed

Insights

Managing chronic heart failure involves targeting the cardiorenal axis with medications like diuretics, ACE-inhibitors, and beta-blockers. Additional drugs, including cardiac glycosides and aldosterone-antagonists, are used for worsening symptoms or specific arrhythmias.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Chronic heart failure (CHF) management requires addressing complex pathophysiology affecting the cardiorenal axis.
  • Current standard pharmacotherapy includes diuretics, ACE-inhibitors, and beta-blockers.

Purpose of the Study:

  • To outline the pharmacotherapeutic strategies for chronic heart failure.
  • To detail the roles of various drug classes in managing CHF and its complications.

Main Methods:

  • Review of standard and supplementary pharmacotherapies for CHF.
  • Discussion of drug indications based on heart failure severity (NYHA classes) and arrhythmias.
  • Exploration of alternative therapies like AT1-antagonitors when ACE-inhibitors are not tolerated.

Main Results:

  • Standard therapy can be augmented with cardiac glycosides for symptom exacerbation or arrhythmias.
  • Aldosterone-antagonists are crucial in NYHA III-IV patients to prevent cardiac remodeling.
  • AT1-antagonists offer an alternative for patients with ACE-inhibitor contraindications or side effects.

Conclusions:

  • Combination therapy, particularly with ACE-inhibitors and AT1-antagonists, can decrease morbidity and hospitalizations.
  • Tailored pharmacotherapy is essential for effective chronic heart failure management.
  • Understanding the cardiorenal axis is key to optimizing CHF treatment.

More Related Videos

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice05:08

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice

Published on: October 3, 2019

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment08:24

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment

Published on: May 25, 2020

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.